Initial Canadian experience with artificial blood (Fluosol-DA-20%) in severely anemic patients

H. J. Stefaniszyn, J. E. Wynands, Tomas Salerno

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Fluosol-DA-20% (FDA), a synthetic perfluorocarbon emulsion with oxygen (O2) carrying capability, has recently become available in North America for clinical trials in severely anemic patients. Three patients have so far received FDA at our institution. All were severely anemic (Hct's 12-15%), and were administered FDA in anticipation of perioperative blood loss. Observations made in these patients indicate that: (a) FDA can act as a plasma expander; (b) no firm conclusions can be made as to whether FDA increases O2 consumption in the absence of directly measured arterial and mixed-venous O2 contents; (c) mixed-venous oxyhemoglobin saturation at high FiO2 increases following FDA administration because a significant proportion of the consumed O2 (24-37% in our patients at FiO2=1.0) is transported by FDA; (d) hemodynamic reactions to a test dose of FDA may occur, and may be serious enough to preclude further FDA administration; and (e) technical recommendations for the administration of FDA should include the use of direct arterial and mixed-venous O2-content determinations, and continuous spectrophotometric mixed-venous oxyhemoglobin saturation monitoring.

Original languageEnglish
Pages (from-to)337-342
Number of pages6
JournalJournal of Cardiovascular Surgery
Volume26
Issue number4
StatePublished - Dec 1 1985
Externally publishedYes

Fingerprint

Blood Substitutes
Oxyhemoglobins
glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination
Fluorocarbons
North America
Emulsions
Hemodynamics
Clinical Trials
Oxygen

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Initial Canadian experience with artificial blood (Fluosol-DA-20%) in severely anemic patients. / Stefaniszyn, H. J.; Wynands, J. E.; Salerno, Tomas.

In: Journal of Cardiovascular Surgery, Vol. 26, No. 4, 01.12.1985, p. 337-342.

Research output: Contribution to journalArticle

@article{6369fd437ffe4a499c32273760632f4e,
title = "Initial Canadian experience with artificial blood (Fluosol-DA-20{\%}) in severely anemic patients",
abstract = "Fluosol-DA-20{\%} (FDA), a synthetic perfluorocarbon emulsion with oxygen (O2) carrying capability, has recently become available in North America for clinical trials in severely anemic patients. Three patients have so far received FDA at our institution. All were severely anemic (Hct's 12-15{\%}), and were administered FDA in anticipation of perioperative blood loss. Observations made in these patients indicate that: (a) FDA can act as a plasma expander; (b) no firm conclusions can be made as to whether FDA increases O2 consumption in the absence of directly measured arterial and mixed-venous O2 contents; (c) mixed-venous oxyhemoglobin saturation at high FiO2 increases following FDA administration because a significant proportion of the consumed O2 (24-37{\%} in our patients at FiO2=1.0) is transported by FDA; (d) hemodynamic reactions to a test dose of FDA may occur, and may be serious enough to preclude further FDA administration; and (e) technical recommendations for the administration of FDA should include the use of direct arterial and mixed-venous O2-content determinations, and continuous spectrophotometric mixed-venous oxyhemoglobin saturation monitoring.",
author = "Stefaniszyn, {H. J.} and Wynands, {J. E.} and Tomas Salerno",
year = "1985",
month = "12",
day = "1",
language = "English",
volume = "26",
pages = "337--342",
journal = "Journal of Cardiovascular Surgery",
issn = "0021-9509",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Initial Canadian experience with artificial blood (Fluosol-DA-20%) in severely anemic patients

AU - Stefaniszyn, H. J.

AU - Wynands, J. E.

AU - Salerno, Tomas

PY - 1985/12/1

Y1 - 1985/12/1

N2 - Fluosol-DA-20% (FDA), a synthetic perfluorocarbon emulsion with oxygen (O2) carrying capability, has recently become available in North America for clinical trials in severely anemic patients. Three patients have so far received FDA at our institution. All were severely anemic (Hct's 12-15%), and were administered FDA in anticipation of perioperative blood loss. Observations made in these patients indicate that: (a) FDA can act as a plasma expander; (b) no firm conclusions can be made as to whether FDA increases O2 consumption in the absence of directly measured arterial and mixed-venous O2 contents; (c) mixed-venous oxyhemoglobin saturation at high FiO2 increases following FDA administration because a significant proportion of the consumed O2 (24-37% in our patients at FiO2=1.0) is transported by FDA; (d) hemodynamic reactions to a test dose of FDA may occur, and may be serious enough to preclude further FDA administration; and (e) technical recommendations for the administration of FDA should include the use of direct arterial and mixed-venous O2-content determinations, and continuous spectrophotometric mixed-venous oxyhemoglobin saturation monitoring.

AB - Fluosol-DA-20% (FDA), a synthetic perfluorocarbon emulsion with oxygen (O2) carrying capability, has recently become available in North America for clinical trials in severely anemic patients. Three patients have so far received FDA at our institution. All were severely anemic (Hct's 12-15%), and were administered FDA in anticipation of perioperative blood loss. Observations made in these patients indicate that: (a) FDA can act as a plasma expander; (b) no firm conclusions can be made as to whether FDA increases O2 consumption in the absence of directly measured arterial and mixed-venous O2 contents; (c) mixed-venous oxyhemoglobin saturation at high FiO2 increases following FDA administration because a significant proportion of the consumed O2 (24-37% in our patients at FiO2=1.0) is transported by FDA; (d) hemodynamic reactions to a test dose of FDA may occur, and may be serious enough to preclude further FDA administration; and (e) technical recommendations for the administration of FDA should include the use of direct arterial and mixed-venous O2-content determinations, and continuous spectrophotometric mixed-venous oxyhemoglobin saturation monitoring.

UR - http://www.scopus.com/inward/record.url?scp=0022255110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022255110&partnerID=8YFLogxK

M3 - Article

C2 - 4019576

AN - SCOPUS:0022255110

VL - 26

SP - 337

EP - 342

JO - Journal of Cardiovascular Surgery

JF - Journal of Cardiovascular Surgery

SN - 0021-9509

IS - 4

ER -